Humacyte Inc (HUMA)
6.33
-0.09
(-1.40%)
USD |
NASDAQ |
May 17, 16:00
6.35
+0.02
(+0.32%)
After-Hours: 20:00
Humacyte Cash from Financing (Quarterly): 62.80M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 62.80M |
| December 31, 2023 | -0.335M |
| September 30, 2023 | -0.764M |
| June 30, 2023 | 6.015M |
| March 31, 2023 | -0.409M |
| December 31, 2022 | -0.212M |
| September 30, 2022 | -0.289M |
| Date | Value |
|---|---|
| June 30, 2022 | -0.484M |
| March 31, 2022 | -0.461M |
| December 31, 2021 | 6.546M |
| September 30, 2021 | 242.08M |
| June 30, 2021 | -0.916M |
| March 31, 2021 | 19.27M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.916M
Minimum
Jun 2021
242.08M
Maximum
Sep 2021
25.60M
Average
-0.289M
Median
Sep 2022
Cash from Financing (Quarterly) Benchmarks
| Aquestive Therapeutics Inc | 81.74M |
| Adial Pharmaceuticals Inc | 3.384M |
| Gritstone Bio Inc | -0.379M |
| Precision BioSciences Inc | 40.10M |
| Puma Biotechnology Inc | 0.00 |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -27.35M |
| Cash from Investing (Quarterly) | -0.391M |
| Free Cash Flow | -83.53M |
| Free Cash Flow Per Share (Quarterly) | -0.2563 |
| Free Cash Flow Yield | -12.61% |